期刊文献+

小剂量伊那普利治疗肾移植术后红细胞增多症的疗效与副反应观察 被引量:3

Therapeutic efficacy of low dose of enalapril in polycythemia following renal transplantation
下载PDF
导出
摘要 目的:观察小剂量伊那普利治疗肾移植术后红细胞增多症的效果及安全性。方法:46例肾移植后红细胞增多症患者随机分为两组:小剂量组(n=29)和常规剂量组(n=17)。分别应用血管紧张素转换酶抑制剂伊那普利小剂量和常规剂量治疗,用药期间观察患者的外周血红细胞数、血红蛋白、红细胞压积和血压的变化及不良反应。结果:服用伊那普利2~3个月,两组患者外周血红细胞数、血红蛋白及红细胞压积降至正常水平.但常规剂量组出现低血压5例,肾功能损害2倒.而小剂量组仅2例在用药期间出现低血压,予以伊那普利减量后血压恢复正常。结论:小剂量血管紧张素转换酶抑制剂对肾移植术后红细胞增多症的治疗是安全和有效的。 Objective: To observe the therapeutic effect and safety of low dose of enalaprii on erythromatosis following renal transplantation. Methods: Forty six patients with postrenai transplant polycythemia were randomly divided into two groups: treatment group (n=29) and control group (n=17) received low (5 mg/d) and usual dose (20 mg/d) of enalaprii, respectively. RBC count, hemoglobin and hematocrit level, blood pressure, and side effects in all patients were observed during therapy. Results: RBC count, hemoglobin and hematocrit level recovered nomaliy 2-3 months after treatment in all patients. In control group, hypotension and impairment of renal function occurred in 5 and 2 cases, respectively; in treatment group, only 2 cases were suffered from reversible hypotension. Conclusion: Low dose of enalaprii is safe and effective for the treatment of postrenai transplant polycythemia.
出处 《广东医学院学报》 2006年第5期454-455,共2页 Journal of Guangdong Medical College
关键词 肾移植 红细胞增多症 血管紧张素转换酶抑制药 renal transplantation polycythemia angiotensin-converting enzyme inhibitor
  • 相关文献

参考文献5

  • 1邱建新,谢桐.肾移植后继发性红细胞增多症[J].国外医学(泌尿系统分册),1994,14(4):151-155. 被引量:10
  • 2SINGH V,SUD K,MITTAL B R,et al.Postrenal transplant erythrocytosis:risk factors and effectiveness of angiotensin receptor antagonists[J].Transplant Proc,2002,34(8):3191-3192.
  • 3VLAHAKOS D V,MARATHIAS K P,AGROYANNIS B,et al.Posttransplant erythrocytosis[J].Kidney Int,2003,63(4):1187-1194.
  • 4DANOVITCH G M,JAMGOTCHIAN N J,EGGENA P H,et al.Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis.Clinical experience and observation of mechanism[J].Transplantation,1995,60(2):132-137.
  • 5JAVID R,GHAHRAMANI N,MALEK-HOSSEINI S A,et al.Management of posttransplant erythrocytosis with enalapril[J].Transplant Proc,1999,31(8):3226.

共引文献9

同被引文献53

  • 1张亚莉,王红艳,柳红婷.卡托普利治疗肾移植后继发性红细胞增多症临床观察[J].河北医药,2005,27(1):41-41. 被引量:2
  • 2赵勇,覃学勇,丁军平,唐华,朱建坦,丁智仁.贝那普利用于PTE的疗效及安全性的临床观察[J].现代泌尿外科杂志,2005,10(1):20-21. 被引量:1
  • 3侯军,薛武军,田普训,冯新顺,项和立.卡托普利治疗肾移植术后红细胞增多症患者的疗效观察[J].西安交通大学学报(医学版),2005,26(6):616-616. 被引量:1
  • 4王苏娅,王逸民,陈江华,朱琮,寿张飞,吴建勇.肾移植术后环孢素A相关性红细胞增多症[J].肾脏病与透析肾移植杂志,1997,6(2):138-140. 被引量:4
  • 5张之南.血液病诊断及疗效标准[M].2版.北京:科学出版社. 1997:237-243.
  • 6Prakash J, Singh S, Behur SK, et al. Early posttransplant erythrocytosis in renal allograft recipients [J]. J Assoc Physicians India, 2010, 58: 574-576.
  • 7Vlahakos DV, Marathias KP, Agroyannis B, et al. Posttransplant erythrocytosis [ J] . Kidney Int, 2003, 63 (4): 1187-1194.
  • 8Razeghi E, Kaboli A, Pezeshki ML, et al. Risk factors oferythrocytosis post renal transplantation [ J ]. Saudi J Kidney Dis Transpl, 2008, 19 (4) : 559-563.
  • 9Danovitch GM, Jamgotchian NJ, Eggena PH, et al. Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis, clinical experience and observation of mechanism [ J ]. Transplantation, 1995, 60 (2): 132-137.
  • 10Singh V, Sud K, Mittal BR, et al. Postrenal transplant erythrocytosis : risk factors and effectiveness of angiotensin receptor antagonists [ J ] . Transplant Proc, 2002, 34 (8): 3191-3192.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部